Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307427 | PMC |
| http://dx.doi.org/10.1016/j.jscai.2024.101977 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Coronary Angioplasty with Drug-Coated Balloons: Pharmacological Foundations, Clinical Efficacy, and Future Directions.
Medicina (Kaunas)
August 2025
Emergency Clinical Hospital Dr. Bagdasar-Arseni, 041915 Bucharest, Romania.
Drug-coated balloons (DCBs) have transformed percutaneous coronary intervention (PCI) by delivering antiproliferative drugs directly to the arterial wall, offering a stent-less approach that mitigates the risks associated with permanent metallic implants. Initially developed for in-stent restenosis (ISR), DCBs have demonstrated robust efficacy in reducing neointimal hyperplasia and target lesion revascularization (TLR) rates across diverse coronary lesions, including small vessel disease (SVD), de novo lesions, and complex anatomies such as bifurcation lesions. Paclitaxel-coated balloons have long been the cornerstone of DCB therapy due to their established clinical outcomes, but sirolimus-coated balloons are emerging as a promising alternative with potentially superior safety profiles and sustained drug release.
View Article and Find Full Text PDFSite-Specific Antithrombotic Therapy: 24-Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple-Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus.
Catheter Cardiovasc Interv
August 2025
Cardiac Investigation Unit, Auckland City Hospital, Auckland, New Zealand.
Background: DESyne BDS Plus represents a novel triple drug therapy (TRx) applied on a coronary stent platform eluting the antiproliferative drug Sirolimus along with two anticoagulants (Rivaroxaban and Argatroban) to reduce the site-specific thrombotic risk.
Aims: To assess the feasibility and safety of this novel device against a contemporary drug-eluting stent.
Methods: This prospective, multicenter randomized (1:1) trial included 202 patients assigned between the device group (DESyne BDS Plus) and the control group (DESyne X2).
SUV39H1 Regulates KLF4 and Chromatin Remodeling in Smooth Muscle Cell Phenotypic Plasticity.
Arterioscler Thromb Vasc Biol
August 2025
Department of Medicine (Cardiovascular Medicine), Yale University School of Medicine, New Haven, CT. (P.C., R.C., A.J.S., B.J.O., J.M.H., Y.X., J.H., K.A.M.).
Background: Reversible DNA methylation contributes to vascular smooth muscle cell (VSMC) phenotypic plasticity. This plasticity contributes to vascular growth and remodeling but also underlies pathologies, including intimal hyperplasia. We investigated the role of SUV39H1 (suppressor of variegation 3-9 homolog 1), a histone methyltransferase that generates trimethylation at histone H3 lysine 9 (H3K9me3), a repressive heterochromatin-associated epigenetic mark, in VSMC plasticity.
View Article and Find Full Text PDFImpact of alirocumab on neoatherosclerosis formation and vessel healing after drug-eluting stent implantation in patients with acute myocardial infarction: a substudy of the PACMAN-AMI trial.
Int J Cardiovasc Imaging
September 2025
Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.
Higher on-treatment levels of low-density lipoprotein cholesterol in statin-treated patients were reportedly associated with the occurrence of neoatherosclerosis after drug-eluting stent (DES) implantation. We aimed to investigate the impact of alirocumab added to high-intensity statin therapy on neoatherosclerosis formation among patients with acute myocardial infarction (AMI) treated with DES. This was a pre-specified substudy of the PACMAN-AMI trial, a randomized, double-blind trial comparing alirocumab versus placebo added to high-intensity statin therapy in AMI patients.
View Article and Find Full Text PDFPreclinical Assessment of a Novel Polymer-Free Hybrid Drug Eluting Stent.
J Cardiovasc Transl Res
August 2025
Department of Cardiovascular Diseases, German Heart Center Munich, Technical University Munich University Hospital, Lazarettstraße 36, 80636, Munich, Germany.
We aimed to evaluate a novel polymer-free hybrid drug eluting stent (DES) relative to benchmark devices and specific controls addressing singular components of the test device in a juvenile pig model of coronary stenting. 80 stents were implanted in 28 juvenile pigs and evaluated at 28 and 90 days using quantitative coronary angiography and histopathology (n = 10 per group). Scanning electron microscopy was used at 14 days to assess early re-endothelialization (n = 3 per group).
View Article and Find Full Text PDF